Hum. Reprod. Advance Access published online on September 22, 2006
Human Reproduction, doi:10.1093/humrep/del254
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Center for Human Reproduction, New York, NY; The Foundation for Reproductive Medicine, Chicago, IL; Department of Epidemiology and Social Medicine and Department of Obstetrics and Gynecology and Women’s Health, Albert Einstein College of Medicine, Bronx, NY
* To whom correspondence should be addressed. BACKGROUND: The aim of this study was to investigate the effect of treatment with dehydroepiandrosterone (DHEA) on fertility outcomes among women with diminished ovarian reserve. MATERIALS AND METHODS: This is a case-control study in an academically affiliated private infertility centre. Twenty-five women with significantly diminished ovarian reserve had one IVF cycle before and after DHEA treatment, with otherwise identical hormonal stimulation. Women received 75 mg of DHEA daily (25 mg three times daily) for an average of 17.6 ± 2.13 weeks. We performed a comparison of IVF outcome parameters, before and after DHEA treatment, including peak estradiol (E2) levels, oocyte and embryo numbers, oocyte and embryo quality and embryo transfer statistics. RESULTS: Paired analysis of IVF cycle outcomes in 25 patients, who underwent cycles both before and after DHEA supplementation, demonstrated significant increases in fertilized oocytes (P < 0.001), normal day 3 embryos (P = 0.001), embryos transferred (P = 0.005) and average embryo scores per oocyte (P < 0.001) after DHEA treatment. CONCLUSION: This study confirms the previously reported beneficial effects of DHEA supplementation on ovarian function in women with diminished ovarian reserve.
Received April 3, 2006
Revised May 22, 2006
Accepted May 27, 2006
Article
Effect of dehydroepiandrosterone on oocyte and embryo yields, embryo grade and cell number in IVF
David Barad 1 * and Norbert Gleicher 2
2 Center for Human Reproduction, New York, NY; The Foundation for Reproductive Medicine, Chicago, IL; Department of Obstetrics and Gynecology, Yale University School of Medicine, New Haven, CT, USA
David Barad, E-mail: dbarad{at}optonline.net
![]()
Abstract ![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
K. Lossl, C. Y. Andersen, A. Loft, and A. N. Andersen Reply: Androgen priming before ovarian stimulation for IVF Hum. Reprod., September 5, 2008; (2008) den320v1. [Full Text] [PDF] |
||||
![]() |
N. Gleicher and D. H. Barad Androgen priming before ovarian stimulation for IVF Hum. Reprod., August 20, 2008; (2008) den319v1. [Full Text] [PDF] |
||||
![]() |
K. Lossl, C. Y. Andersen, A. Loft, N.L.C. Freiesleben, S. Bangsboll, and A. N. Andersen Short-term androgen priming by use of aromatase inhibitor and hCG before controlled ovarian stimulation for IVF. A randomized controlled trial Hum. Reprod., August 1, 2008; 23(8): 1820 - 1829. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. T. Page, A. M. Matsumoto, W. J. Bremner, M. Yasuda, S. Horie, T. T. Perls, N. Gleicher, D. Barad, K. S. Nair, and G. Smith DHEA and Testosterone in the Elderly N. Engl. J. Med., February 8, 2007; 356(6): 635 - 637. [Full Text] [PDF] |
||||

